罗格列酮(rosiglitazone,商品名Avandia)是第2种噻唑烷二酮衍生物,现已获美国FDA批准上市,单用或与二甲双胍合用治疗Ⅱ型糖尿病。 药动学:罗格列酮口服后易于吸收,同食物同服或不与食物同服均可。约1h可达血药峰值,消除半衰期为3～4h。主要在肝内通过C7YP2C8代谢,其次被2C9代谢。最终作为结合代谢物排泄,2/3随尿排出,1/3随粪便排出。 Rosiglitazone (Avandia), the second thiazolidinedione derivative, has now been approved by the US FDA for use in the treatment of type 2 diabetes alone or in combination with metformin. Pharmacokinetics: Rosiglitazone is easy to absorb after oral administration, with the same or without food and clothing with the food can be. About 1h up blood peak, eliminating half-life of 3 ~ 4h. Mainly in the liver through C7YP2C8 metabolism, followed by 2C9 metabolism. Eventually excreted as a binding metabolite, 2/3 with the urine, and 1/3 with the excrement.